A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial

A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial

Abstract A prospective trial has not been performed to investigate associations between quality of life (QOL), adverse events (AEs), and overall survival (OS) in the first‐line treatment with cetuximab plus standard chemotherapy for advanced/metastatic colorectal cancer (mCRC). Associations between...

Full description

Bibliographic Details
Main Authors: Shigeyoshi Iwamoto, Akira Ooki, Satoshi Morita, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Sudo, Yojiro Hashiguchi, Taichi Yabuno, Junichi Sakamoto, Akihito Tsuji, Masahiko Ando, Kensei Yamaguchi
Format: Article
Language:English
Published: Wiley 2018-09-01
Series:Cancer Medicine
Subjects:
adverse event
Cetuximab
chemotherapy
colorectal cancer
Quality of Life
Online Access:https://doi.org/10.1002/cam4.1623

Internet

https://doi.org/10.1002/cam4.1623

Similar Items